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Abstract  
Human   flavin-­containing  monooxygenase   isoform  3   (hFMO3)   is  an   important  hepatic  
drug-­metabolizing   enzyme,   catalyzing   the   monooxygenation   of   nucleophilic  
heteroatom-­containing   xenobiotics.   Based   on   the   structure   of   bacterial   FMO,   it   is  
proposed   that   a   conserved   asparagine   is   involved   in   both   NADP(H)   and   substrate  
binding.   In  order   to  explore   the   role  of   this  amino  acid   in  hFMO3,   two  mutants  were  
constructed.  In  the  case  of  N61Q,  increasing  the  steric  hindrance  above  the  flavin  N5-­
C4a   causes   poor   NADP(H)   binding,   destabilizing   the   catalytic   FAD   intermediate,  
whereas  the  introduction  of  a  negatively  charged  residue,  N61D,  interferes  mainly  with  
catalytic   intermediate   formation   and   its   stability.   To   better   understand   the   substrate-­
enzyme   interaction,   in   vitro   as   well   as   in   silico   experiments   were   carried   out   with  
methimazole  as  substrate.  Methimazole  is  a  high-­affinity  substrate  of  hFMO3  and  can  
competitively  suppress  the  metabolism  of  other  compounds.  Our  results  demonstrate  
that  methimazole  Pi-­stacks  above  the  isoalloxazine  ring  of  FAD  in  hFMO3,  in  a  similar  
way  to  indole  binding  to  the  bacterial  FMO.  However,  for  hFMO3  indole  is  found  to  act  
as   a   non-­substrate   competitive   inhibitor.   Finally,   understanding   the   binding  mode   of  
methimazole  and  indole  could  be  advantageous  for  development  of  hFMO3  inhibitors,  
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1.   Introduction  
  
During  the  last  few  decades  a  large  number  of  flavin-­containing  monooxygenases  
(FMOs)   have   been   studied   revealing   their   specificity   to   catalyze   a   wide   range   of  
oxidative  reactions,  which  makes  this  class  of  enzymes  of  great  interest  for  synthetic  as  
well  as  biotechnological  applications  both  in  the  chemical  and  medical  fields  [1-­4].  One  
member  of  this  class,  human  flavin-­containing  monooxygenase  isoform  3  (hFMO3),  is  
involved  in  the  metabolism  of  a  wide  variety  of  nitrogen-­  and  sulfur-­containing  chemicals  
[2,  5].  
In  general  terms,  the  FMO  catalytic  cycle  includes  flavin  reduction  by  NADPH,  O2  
diffusion/activation,  C4a-­(hydro)peroxyflavin  intermediate  formation,  substrate  oxidation  
and   finally,   flavin  regeneration   [6].  The  oxidized   flavin  prosthetic  group   is   reduced  by  
NADPH  through  a  hydride  transfer  giving  rise  to  the  reduced  flavin  and  NADP+  [6].  For  
FMO,   conformational   changes   and   sidechain   movements   are   thought   to   occur   to  
accommodate  the  binding  of  NADPH  and  the  subsequent  flavin  reduction  [7].  
The   reduced   flavin   will   further   react   with   O2   to   form   the   C4a-­hydrperoxyflavin  
intermediate   which  must   be   protected   from   decay   in   order   to   further   react   with   the  
substrate  otherwise  the  uncoupling  reaction  will  result  in  hydrogen  peroxide  formation  
[8].   Flavoproteins   adopt   different   mechanisms   to   provide   an   ideal   physicochemical  
environment   for   the   formation   and   most   importantly   the   stabilization   of   C4a-­
(hydro)peroxyflavin  intermediate.  In  FMO,  after  flavin  reduction,  NADP+  remains  bound  
to  the  enzyme.  The  nicotinamide  ring  of  NADP+  is  stacked  with  the  isoalloxazine  ring  
and  its  amide  nitrogen  within  hydrogen-­bond  distance  from  the  flavin  N5-­H  [7,  9].  Once  
formed,  the  C4a-­(hydro)peroxyflavin  oxygenates  the  substrate  to  yield  the  product.  
Collectively   in   FMO,   the   flavoprotein-­mediated   catalytic   reaction   is   primarily  
controlled  and  modulated  by  NADPH  binding  for  the  flavin  reduction  and  NADP+  binding  
for  the  C4a-­hydrperoxyflavin  intermediate  stability.  
To  date,  there  are  only  two  FMO  proteins  with  known  crystal  structure,  bacterial  FMO  
from   Methylophaga   sp.   Strain   SK1   (bFMO)   [7]   and   yeast   FMO   from  
schizosaccharomyces   pombe   (yFMO)   [9],   showing   a   catalytic   microenvironment  
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defined  by  nicotinamide  moiety  of  NADP+,  the  side-­chain  of  a  conserved  Asn  residue,  
and  the  flavin  N5-­C4a  [7,  9].  The  conserved  Asn  residue  located  at  the  entrance  of  the  
microenvironment  forms  hydrogen  bonds  (H-­bonds)  with  both  NADP+  and  FAD  (flavin  
adenine  dinucleotide)  in  bFMO  and  yFMO.  Of  these,  the  H-­bond  between  OD1  atom  of  
the  conserved  Asn  residue  and  O2D  atom  of  NADP+  is  favourable  for  NADP+  binding.  
The  binding  of  NADP+  can  protect   the  C4a-­(hydro)peroxyflavin   intermediate   from  
decay  before  substrate  access.  The  substrate-­enzyme  co-­crystal  structures  of  bFMO  
(PDB  ID:  2XVJ)  and  yFMO  (PDB  ID:2GVC)  show  special  Pi-­stacking  binding  modes  of  
indole  and  methimazole  (MMI).  After  analyzing  the  structures  of  bFMO  (PDB  ID:  2XVJ)  
and  yFMO  (PDB  ID:  2GVC),  the  conserved  Asn  is  the  only  residue  within  5  Å  from  the  
flavin  N5-­C4a  above  FAD.  Therefore,   in  FMO,   this  Asn   is   highly   likely   to  be  directly  
involved  in  substrate  binding.  Taken  together,  Asn  61  is  an  ideal  target  to  investigate  the  
binding  of  NADP(H)  and  substrate  to  hFMO3.  
Any  compound  containing  a  soft  nucleophilic  heteroatom  gaining  access  to  the  C4a-­
hydrperoxyflavin   intermediate   can   be   a   potential   hFMO3   substrate.   Compounds  
containing  a  single  positively  charged  atom  are  excellent  substrates,  such  as   tertiary  
amines  [1,  10].  In  this  paper,  in  order  to  investigate  the  NADP(H)  and  substrate  binding  
in   hFMO3,   two   rationally   designed   mutants   were   generated:   N61D   to   introduce   a  
negatively   charged   residue   which   may   be   helpful   for   NADP+   and   substrate   binding  
through  electrostatic  interaction  and,  N61Q  to  pose  a  steric  hindrance  above  flavin  N5-­
C4a   which  maybe   favourable   for   shielding   C4a-­hydroperoxyflavin   intermediate   from  
solvent   attack   (intermediate   stability   is   crucial   for   oxygen   transfer   to   oxygenate   the  
substrate).  In  both  mutants,  the  OD1  atom  of  the  mutated  residue  is  still  present  and  
available  for  possible  H-­bonding  to  O2D  of  NADP+,  which  is  important  for  NADP+  binding.  
The  mutants  were  heterologously  expressed  in  E.  coli  and  purified.  This  was  followed  
by  in  silico  molecular  docking  experiments  combined  with  in  vitro  steady-­state  kinetics,  
microcalorimetric  and  fluorescence  assays.  The  results  obtained  demonstrate  that  both  
mutations  at  this  position  lead  to  poor  NADP(H)  and  substrate  binding  affinity  in  hFMO3.  
In   vitro   and   in   silico   experiments   suggest   that   the   side-­chain   of   the   original   Asn61  
residue  together  with  NADP+  pose  a  protective  barrier  prolonging  the  half-­life  of  C4a-­
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hydroperoxyflavin   intermediate.   Removal   of   this   protective   barrier   results   in   the  
observed  poor  NADP(H)  and  substrate  binding  affinity  in  hFMO3.     
In  addition,   the  binding  mode  of  methimazole   is  also   studied  by   in   silico   docking  
experiments  together  with  that  of  indole,  a  non-­substrate  hFMO3  inhibitor.  Since  2011,  
more  and  more  studies  have  concluded  that  inhibition  of  hFMO3  provides  a  therapeutic  
strategy   for   the   treatment   and/or   prevention   of   atherosclerosis   [11-­14].   Although  
complete  inhibition  of  hFMO3  is  undesirable,  its  reduced  activity  might  be  beneficial  [15,  
16].  Understanding  the  special  binding  mode  of  MMI  and  indole  is  helpful  for  developing  
hFMO3-­specific  inhibitors  in  the  future.  
  
2.   Materials  and  Methods  
  
2.1.   Cloning,  expression  and  purification  
The  wild   type  hFMO3  was  previously   cloned   in   our   laboratory   in   the  expression  
vector  pJL2  and  is  the  full-­length  protein  [17,  18].  The  mutants  N61D  and  N61Q  were  
constructed  by  the  standard  QuikChange  mutagenesis  kit  protocol  (Stratagene)  using  
the   wild   type   vector   as   template.   The   primers   used   for   N61D   mutation   were   5’-­
GTCTTTTCCGACTCTTCCAAAGAGATGATGTGTTTCCCA-­3’   and   5’-­
TGGGAAACACATCATCTCTTTGGAAGAGTCGGAAAAGAC-­3’.  The  primers  used   for  
N61Q  mutation  were  5’-­GTCTTTTCCCAGTCTTCCAAAGAGATGATGTGTTTCCCA-­3’  
and  5’-­TGGGAAACACATCATCTCTTTGGAAGACTGGGAAAAGAC-­3’.  The  mutations  
were  confirmed  by  DNA  sequencing.  
E.  coli  JM109  cells  were  subsequently  transformed  with  the  resulting  IPTG-­inducible  
expression  plasmids.  Protein  purification  was  performed  by  Ni-­affinity  chromatography  
following  a  DEAE  ion  exchange  column  as  described  previously  [17,  18].  
   The   purified   proteins   were   characterized   by   spectrophotometer   and   Differential  
Scanning  Calorimetry  (DSC),  in  order  to  confirm  if  the  FAD  cofactor  was  bound.  UV-­vis  
spectra   of   the   purified   proteins   were   recorded   using   a   diode   array   HP-­8453E  
spectrophotometer.   The   concentration   of   the   hFMO3   proteins   was   determined   by  
spectroscopy   with   the   peak   absorbance   at   450   nm   and   an   extinction   coefficient   of  
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11,900  M-­1  cm-­1,  as  previously  described  [17].  
   DSC  experiments  were  carried  out  on  a  Microcal  VP-­DSC  instrument  (Malvern,  USA).  
Scans  were  taken  from  30  °C  to  75  °C  at  a  scan  rate  of  30  °C/h  with  a  rescanning  of  the  
sample  at  the  same  condition  for  the  control  experiments.  The  data  were  analyzed  by  
Origin  software  (MicroCal)  as  also  described  previously  [19].  
  
2.2.   Methimazole  binding  investigation  
The   kinetic   parameters   of   enzyme-­mediated   methimazole   S-­oxidation   were  
determined  spectrophotometrically  at  412  nm.  The  reaction  mixture  contained  50  mM  
phosphate   buffer   pH   7.4,   60  μM   DTNB,   30  μM   DTT,   0.82  μM   enzyme,   a   series   of  
methimazole  concentration  and  1  mM  NADPH.  Reactions  were  carried  out  at  37  °C.  
The  methimazole  binding  modes  were  explored  by  fluorescence  experiments  and  
competitive  displacement  assays.  
Methimazole  binding  above  the  isoalloxazine  ring  may  result  in  fluorescent  changes  
of   FAD.   The   fluorescence   experiments   were   performed   on   a   Perkin-­Elmer   LS-­55  
spectrofluorimeter  equipped  with  a  thermostated  cell  holder.  12.8  μM  protein  dissolved  
in  10  mM  phosphate  buffer  (pH  7.4)  in  the  presence  of  0,  4,  8  and  12  mM  methimazole  
was  used  for  the  assay.  Same  experiments  performed  in  the  absence  of  protein  were  
used  as  the  control.  Excitation  and  emission  slit  widths  were  set  to  10.  Emission  spectra  
of   protein   were  measured   at   a   scan   rate   of   100   nm/min   from   480   to   600   nm,   with  
excitation   at   450   nm.   Five   accumulations   were   recorded   and   averaged   for   each  
spectrum.   Fluorescence   intensity   was   corrected   for   dilution.   The   experiments   were  
carried  out  at  25  °C.  
The  crystal  structures  of  bFMO  (PDB  ID:  2XVJ)  and  yFMO  (PDB  ID:  2GVC)  show  
similar  Pi-­stacking  binding  modes  of  indole  and  methimazole  above  FAD.  If  indole  and  
methimazole  adopt  same  binding  modes  in  hFMO3,  the  competitive  binding  of  indole  
above  isoalloxazine  ring  of  FAD  will  suppress  methimazole  S-­oxidation.  Therefore,  the  
effects  of  indole  on  MMI  S-­oxygenation  was  determined.  The  reaction  mixture  contained  
50  mM  phosphate  buffer  (pH  7.4),  60  μM  DTNB,  30  μM  DTT,  0.82  μM  hFMO3,  1  mM  
NADPH  and  methimazole  (MMI  concentration  is  around  the  Km  value  of  the  enzyme),  
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in   the   presence   of   0,   1,   2,   4  mM   indole,   respectively.   The  N-­oxidize   products   were  
analyzed  colorimetrically  by  monitoring  the  absorbance  at  412  nm,  37  °C.  
bFMO  can  oxygenate   the   indole   to  produce   indoxyl   followed  by  a  non-­enzymatic  
reaction  to  yield  the  indigo  [20].  Here,  HPLC  (Agilent-­1200,  Agilent  Technologies,  U.S.A.)  
analysis   was   used   to   confirm   if   indole   is   a   hFMO3   substrate.   The   reaction  mixture  
contained  1  μM  WT-­hFMO3,  0.5  mM  indole  and  1  mM  NADPH,  50  mM  phosphate  buffer  
(pH  7.4),   in  a   total   volume  of  200  μl.  The   reactions  were  performed  at  37   °C   for  30  
minutes  before  termination  by  100  μl  ice-­cold  acetonitrile.  The  resulting  reaction  mixture  
was  analyzed  by  HPLC  equipped  with  4.6  ×  150  mm  5  μm  Eclipse  XDB-­C18  column,  at  
room  temperature.  The  mobile  phases  consisted  of  45%  acetonitrile  and  55  %  0.1%  
formic  acid  in  water,  and  an  isocratic  elution  was  used.  Same  experiments  performed  in  
the  absence  of  WT-­hFMO3  were  used  as  the  control.  
The   presence   of   substrate   accelerates   NADPH   consumption   in   WT-­hFMO3.  
Therefore,  NADPH  consumption  in  the  absence  and  presence  of  indole  was  monitored  
at   340   nm   spectrophotometrically.   In   detail,   the   reaction   mixture   contained   50   mM  
phosphate  buffer  (pH  7.4),  0.8  μM  WT-­hFMO3,  0.2  mM  NADPH  in  the  presence  of  0,  2,  
4  mM  indole,  respectively.  
The  type  of  inhibitory  effect  of  indole  on  wild-­type  hFMO3-­mediated  methimazole  S-­
oxidation  was  determined  by  Lineweaver-­Burk  plot.  The  reaction  mixture  consisted  of  
different  concentrations  of  MMI   (0.02-­0.32  mM),  60  μM  DTNB,  30  μM  DTT,  0.82  μM  
hFMO3,  0.5  mM  NADPH,  50  mM  phosphate  buffer  (pH  7.4),  in  the  presence  of  different  
concentrations  of  indole  (0,  1,  2,  3  mM).  The  absorbance  changes  were  recorded  at  412  
nm.  
  
2.3.   In  silico  mutagenesis  and  molecular  docking  
Structural  views  of  MMI  and  NADP(H)  binding  modes  to  the  protein  were  explored  
by  molecular  docking  experiments.  As   the  3D  structure  of  hFMO3   is  not  available,  a  
structural  model   built   by   homology  modelling  was   used   as   the   template   for   in   silico  
mutation   [21].   The   templates   used   for   the   latter   3D  model  were   bFMO   (with   23.0%  
sequence  identity  and  40.4%  sequence  homology  to  hFMO3)  [7]  and  yFMO  (with  21.5%  
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sequence  identity  and  37.5%  sequence  homology  to  hFMO3)  [9].  The  “swap”  function  
in   YASARA   [22]   was   used   to   generate   the   N61D   and   N61Q  mutants.   The  mutated  
residue  was  then  optimized  by  screening  of  the  rotamer  libraries  to  fully  relax  the  steric  
clashes.  The  refined  mutant  models  were  docked  with  NADP(H)  and  MMI  to  investigate  
the  changes  of  catalytic  pocket  shape  and  NADP(H)  binding  modes  after  mutation,  and  
the  results  were  analyzed  by  Discovery  Studio  Visualizer  (DS  Visualizer).  The  NADPH,  
NADP+  and  MMI  used  for  molecular  docking  were  prepared  from  the  crystal  structures  
of  pcDHFR  (PDB  ID:  4IXE)  [23],  bFMO  (PDB  ID:  2VQ7)  [7]  and  yFMO  (PDB  ID:  2GVC)  
[9],  respectively  and,  the  docking  experiments  were  performed  by  YASARA  Structure  
package  [22].  For  NADP+  and  MMI,	  prior  to  the  docking  experiments,  dioxygen  binding  
at  the  C4a  position  of  FAD  was  modelled  [7]  and  optimized  by  multiple  Clean  Geometry  
function  in  DS  Visualizer.  The  docking  procedure  includes  a  global  docking  experiment  
followed  by  a  local  docking  yielding  the  final  docking  result  as  described  previously  [21],  
and   the  best  docking  mode  with   the  highest  binding  energy  was   finally  selected  and  
subjected  to  energy  minimization  using  YASARA  Structure  package.  
In  general,  using  YASARA,  docking  runs  of  the  ligand  to  receptor  yield  results  sorted  by  
binding  energy  where  more  positive  energies   indicate  stronger  binding  and  negative  
energies  equate  to  no  binding.  After  global  docking  the  best  binding  mode  (pose)  was  
selected  based  on  the  best  binding  energy.  The  complexes  were  then  subjected  to  999  
runs  of  Local  Docking  yielding  the  final  docked  binding  modes.     
  
2.4.   NADPH  binding  assay  
Steady-­state  activity  of  NADPH  oxidase  for  WT-­hFMO3,  N61D  and  N61Q  mutants  
were   determined   spectrophotometrically   by  monitoring   the   decrease   of  NADPH  with  
time  at  340  nm.  The  reaction  mixture  contained  50  mM  phosphate  buffer  pH  7.4,  0.2  μM  
enzyme  with  various  concentrations  of  NADPH.  Reactions  were  carried  out  at  37  °C  for  
20  min.  
The  pre-­steady-­state  activity  of  NADPH  oxidase  for  WT-­hFMO3,  N61D  and  N61Q  
mutants  were  determined  by  a  stopped-­flow  apparatus  (SF-­61,  HI-­TECH  scientific,  UK)  
equipped  with  a  diode  array  detector.  The  kinetic  parameters  of  flavin  reduction  were  
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determined  in  an  anaerobic  glove  box  (Belle  Technology,  UK)  by  mixing  20  μM  protein  
with  various  concentrations  of  NADPH  using  the  stopped-­flow  instrument  as  previously  
described  [19,  24].  Spectra  (300  -­  700  nm)  were  collected  over  time  and  the  absorbance  
changes   at   450   nm  were   analysed   by   Kinetic   Studio   Version   3.0   software   package  
resulting  in  the  rates  of  flavin  reduction.  Kinetic  parameters  were  determined  from  the  
reaction  rates  with  corresponding  NADPH  concentrations  fitted  to  equation  1  using  non-­
linear  regression  analysis  (SigmaPlot  12.0).  𝑘"#$ = &'()[+,-./]1)2[+,-./]                                                                                                                                                                  (Eq.  1)  
  
2.5.   NADP+  binding  assay  
Association   constant   (Ka)   of   NADP+   to   the   mutants   was   determined   by   ITC  
experiments  performed  with   the   ITC200  calorimeter   (Malvern,  USA).  The  experiments  
were  performed  by  titration  of  NADP+  (20  mM  for  N61D  and  2  mM  for  N61Q)  into  a  20  
μM  protein  solution  as  described  previously  [19].  The  experimental  data  were  corrected  
for  the  heat  of  dilution  of  NADP+  solution  by  performing  separate  titrations  against  only  
buffer.  The  results  were  analyzed  by  nonlinear  regression  using  “One  Set  of  Sites  curve”  
fitting  model  (MicroCal  iTC200  Origin)  resulting  in  the  calculated  value  of  Ka.  Finally,  the  
dissociation  constant  (Kd)  was  calculated  as  it  is  equal  to  the  inverse  of  the  Ka  values.  
NADP+  binding  affinity  in  FMO  is  associated  with  the  intermediate  stability.  The  C4a-­
hydroperoxyflavin   intermediate   is   monitored   by   the   stopped-­flow   apparatus.   The  
enzyme  was  first  fully  reduced  by  equimolar  amounts  of  NADPH  under  anaerobiosis,  
then  mixed  with  air-­saturated  buffer  and  monitored  over  time  by  stopped-­flow.  The  data  
were  subsequently  analyzed  by  Kinetic  Studio  Version  3.0  software  package.  
  
3.   Results  
  
3.1.   Purification  of  mutants  and  Tm  measurements  
WT-­hFMO3   and   its   two   mutants   were   heterologously   expressed   in   E.   coli   and  
purified   using   protocols   previously   reported   [17,   18].   The  mutants  were   successfully  
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purified  (Fig.  S1)  with  yields  of  9.6  and  8.5  mg  per  litre  of  culture  for  N61Q  and  N61D,  
respectively.  On  average  the  purified  mutants  had  a  purity  index,  A280/A450,  of  around  
11  similar  to  the  data  of  the  WT-­hFMO3.  
The   purified   proteins   were   initially   characterized   spectrophotometrically.   Fig.   1  
shows  the  UV-­vis  spectra  of  WT-­hFMO3,  N61Q  and  N61D  with  the  maxima  around  375  
and  450  nm.  The  mutant  spectra  are  very  similar  to  those  of  the  WT-­hFMO3  indicating  
that  the  mutations  have  not  affected  the  FAD  incorporation  in  the  protein.  
After   the   initial   UV-­vis   characterization   of   the  mutants,   the   thermostability   of   the  
purified   proteins   was   determined   by   DSC   as   mentioned   in   Materials   and   Methods  
section.  For  all  three  proteins,  a  single  symmetrical  peak  was  not  observed  suggesting  
that  the  thermal  unfolding  of  hFMO3  and  its  mutants  is  not  a  simple  two-­state  process  
(Table  S1-­  according  to  Lepock  et  al.  [25]  and  Vermeer  &  Norde,  [26])  and,  in  line  with  
already   published   data   for   the   WT-­hFMO3   [19].   Two   melting   temperatures   were  
obtained   for  each  mutant  after  deconvolution  of   the   thermographs   (Fig.  S2)  and  are  
reported  in  Table  1.  As  can  be  seen  in  Table  1,  the  calculated  Tm1  values  are  the  same  
for  WT  and  mutant  hFMO3,  around  45°C.  However,  both  mutants  show  a  slight  increase  
in  Tm2  values  compared  to   the  WT-­hFMO3.  At  present,  we  do  not  have  a  conclusive  
answer  as  to  the  origin  of  these  two  Tm  values.  In  general,  this  observation  indicates  
the  existence  of  two  underlying  melting  processes  which  may  be  related  to  two  different  
domains  (NADP+  binding  domain  and  FAD  binding  domain)  of  hFMO3  molecule  [21],  or  
the  presence  of  two  protein  populations  (native  plus  aggregated  forms).  More  studies  
need  to  be  carried  out  to  clarify  this  point.     
  
Table  1  The  melting  temperatures  of  WT-­hFMO3,  N61Q  and  N61D.  
Enzyme   Tm1,  °C   Tm2,  °C     
WT  [19]   45.1  ±  0.1   49.0  ±  0.2     
N61D   45.4  ±  0.1   50.6  ±  0.3     
N61Q   45.7  ±  0.2   51.7  ±  0.2     
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3.2.   Characterization  of  methimazole  binding  by  molecular  docking,  fluorescent  
and  competitive  displacement  assays  
In   the   first   set   of   experiments,   in   order   to   determine   the   catalytic   activity   of   the  
purified   mutant   proteins,   a   well-­known   hFMO3   substrate,   methimazole   [27],   was  
selected.   The   kinetic   parameters   for   N61D-­   and   N61Q-­mediated   methimazole   S-­
oxygenation   were   determined   following   procedures   outlined   in   the   Materials   and  
Methods  section.  Table  2  summarizes   the  data  obtained   in  comparison   to  previously  
published  data  on  WT-­hFMO3.  As  can  be  seen  in  Table  2,  although  some  activity  was  
measurable  (Fig.  S3),  both  mutants  display  a  significant  decrease  in  catalytic  efficiency.  
In  addition,  a  tertiary  amine,   trimethylamine,  another  well-­known  substrate  of  hFMO3  
[27,  28]  was  also  tested,  and  in  this  case  no  N-­oxygenated  product  was  detected  for  
any  of  the  mutants  (data  not  shown).  
  
Table   2   Kinetic   parameters   of   WT   hFMO3   and   its   mutants   toward   methimazole   S-­
oxidation  
  
Enzyme   Km  (μM)   kcat  (min-­1)   kcat/Km     
WT  [19]   14.9  ±  2.0   8.4  ±  0.9   0.56     
N61D   5815.6  ±  2244.7   2.1±  0.2   0.00037     
N61Q   2424.2  ±  523.5   4.2  ±  0.2   0.0017     
  
In  vitro  steady-­state  kinetic  experiments  demonstrated  significantly  lower  activity  of  
these  two  mutants  toward  methimazole.  In  order  to  investigate  if  this  arises  from  different  
substrate   binding   modes,   WT-­hFMO3   and   the   two   mutants   were   docked   with  
methimazole.  Fig.  2a-­c  illustrate  the  best  docking  modes  of  each  of  the  3  proteins  with  
methimazole.  In  all  cases,  methimazole  interacts  with  the  flavin  isoalloxazine  ring  by  Pi-­
stacking  interaction(s).  This  type  of  Pi-­Pi  interaction  has  also  been  seen  in  the  co-­crystal  
structures  of  bFMO  with  indole  (PDB  ID:  2XVJ)  (Fig.  3a)  and  yFMO  with  methimazole  
(PDB   ID:  2GVC)   (Fig.  3b).  For   completeness,   the  same  Pi-­Pi   interactions  have  also  
been  shown  in  Fig.  3C  with  the  hFMO3  model  docked  with  methimazole.     
The  methimazole  binding  mode  was  further  explored  by  in  vitro  experiments  using  
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the  purified  enzymes.  Binding  of  methimazole  above  the  isoalloxazine  ring  in  hFMO3  
can  induce  FAD  fluorescence  changes  (quenching)  which  are  reported  in  Fig.  2  d-­f.  As  
expected,  the  fluorescence  of  the  protein-­bound  FAD  is  already  largely  quenched  by  the  
surrounding  protein  matrix,  and  only  slightly  quenched  after  methimazole  addition.  Fig.  
2a-­b  shows  that,  in  WT-­hFMO3  and  N61Q  mutant,  methimazole  binds  above  FAD  and  
parallel  to  the  isoalloxazine  ring,  maximizing  the  overlap  of  the  Pi  system.  In  these  two  
proteins,   titration   with   increasing   amounts   of   methimazole   leads   to   even   more  
quenching  and  therefore  a  decrease  in  the  fluorescence  signal  (Fig.  2d  and  2e).  While  
for   N61D   mutant,   Fig.   2c   shows   that   methimazole   adopts   a   T-­shaped   Pi-­stacking  
interaction,  which  results  in  no  further  quenching  or  decrease  in  the  fluorescent  signal  
upon  titration  with  methimazole  (Fig.  2f).  This  T-­shaped  Pi-­stacking  interaction  in  N61D  
mutant,   is   in   line   with   its   observed   poor   methimazole   binding   affinity   (Table   2)   and  
increased  Pi-­stacking  distance  (Fig.  2c).     
In  vitro  experiments  were  carried  out  in  the  presence  of  indole  to  further  characterize  
the  observed  differences  in  methimazole  binding  and  the  results  are  shown  in  Fig.  4a-­
c.   As   can   be   seen   in   Figure   4,   the   presence   of   indole   suppresses  methimazole   S-­
oxidation.   Especially   for   WT-­hFMO3,   80%   of   the   hFMO3   activity   is   inhibited   in   the  
presence  of  4  mM  indole  (Figure  4a).  This  inhibition  is  also  observed  with  N61Q  and  
N61D  mutants  although  N61D  is  again  least  affected  i.e.  only  20%  inhibition  by  addition  
of  4  mM  indole.  In  order  to  confirm  that  indole  is  acting  as  an  inhibitor  and  that  it  cannot  
be  metabolized  by  hFMO3  control   experiments  were   carried  out  and   the   results  are  
reported  in  Fig.  S4a  and  b.  These  experiments  consisted  of  NADPH  consumption  assay  
in   presence   of   indole   as   well   as   HPLC   analysis   of   the   possible   product   of   indole  
conversion  by  hFMO3.  The  results  of  both  control  experiments  confirmed  that  indole  is  
not  a  substrate  of  hFMO3.  
To   ascertain   the   type   of   inhibition   of   indole   on   hFMO3-­mediated   methimazole   S-­
oxidation,  inhibitory  kinetics  were  studied  using  the  double  reciprocal  Lineweaver-­Burk  
plots  and  the  data  are  shown  in  Fig.  4d.  As  can  be  seen  from  the  plot,  in  the  presence  
of  increasing  amounts  of  indole  the  Km  (slope  of  the  straight  lines)  increases  whereas  
the   Vmax   is   unaffected   (intercept   of   Y-­
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inhibitor  of  hFMO3  when  methimazole  is  used  as  its  substrate.     
Taken  together,  in  silico  docking  results  are  in  line  with  the  in  vitro  experimental  data,  
showing   that   both   indole   and   methimazole   can   competitively   bind   above   the   FAD  
isoalloxazine   ring   through  Pi-­stacking   interaction,   and   that   indole   is   a   non-­substrate  
competitive  inhibitor  of  hFMO3.  
  
3.3.   Pre-­steady-­state  and  steady-­state  kinetic  analysis  of  NADPH  binding     
As  mentioned  earlier,  the  hFMO3-­mediated  catalytic  cycle  contains  both  reductive  
and   re-­oxidative   half   reactions   [29,   30].   As   with   any   other   enzyme,   interfering   with  
different   steps   of   the   catalytic   cycle   is   consequential   for   the   hFMO3   substrate  
oxygenation.   For   the   reductive   half-­reaction,   the   pre-­steady-­state   analysis   using  
stopped-­flow   spectroscopy   demonstrated   that   both   N61Q   and   N61D   mutations   of  
hFMO3  decrease  its  NADPH  binding  affinity  by  6-­  and  19-­folds,  respectively  (Table  3).  
While   for   the  catalytic  constant   (kred)  of   flavin   reduction,  no  significant  changes  were  
observed  for  these  two  mutants  (Table  3).  
  
Table  3  Michalis-­Menten  kinetic  parameters  determined  for  the  reductive  half-­reaction  
of  wild  type  and  mutant  hFMO3     
  
  




（s-­1）     
Wild  type  [19]   0.30  ±  0.10   1.33  ±  0.03     
N61D   5.89  ±  2.99   1.03  ±  0.11#     
N61Q   1.85  ±  0.08   1.51  ±  0.40*     
#P  <  0.05,  *P  >  0.05  compared  to  WT  hFMO3,  one-­way  ANOVA  followed  by  
Student-­Newman-­Keuls  test.  
  
While  for  the  steady-­state  kinetic  experiments,  Table  4  summarizes  the  Km  values  
for  NADPH  oxidase  activities  of  the  two  mutants  which  show  increases  of  16-­  and  2.6-­
folds   for   N61D   and  N61Q,   respectively.   These   higher   Km   values   are   indicative   of   a  
decreased  binding  affinity  for  NADPH  after  mutation,  which  are  in  line  with  the  higher  Kd  
values  reported  in  Table  3.  
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WT  [19]   14.96  ±  3.12   2.25  ±  0.20  
N61D   239.17  ±  45.79**   15.18  ±  1.37***  
N61Q   39.71  ±  12.77*   4.13  ±  0.66**  
*P  <  0.05,  **P  <  0.01,  ***P  <  0.001  compared  to  WT-­hFMO3,  one-­way  ANOVA  
followed  by  Student-­Newman-­Keuls  test.  
  
Pre-­steady-­state  and  steady-­state  kinetics  show  decreased  NADPH  affinity  to  the  
enzyme   after   mutation.   In   order   to   better   understand   the   NADPH   binding   from   a  
structural  point  of  view,  in  silico  docking  experiments  were  carried  out.  Fig.  5  shows  the  
binding  modes  of  NADPH  with  WT-­hMFO3  and  its  two  mutants.  The  distances  of  residue  
61  to  flavin  C4a  and  N5  monitored  by  DS  Visualizer  were  used  to  measure  the  size  of  
the   oxygen   reacting   crevice.   Fig.   5c   shows   that   N61Q   mutation   results   in   an  
enlargement  of   the  pocket  whereas  N61D  mutation  (Fig.  5b)  has  the  opposite  effect,  
although  with  a  similar   side-­chain.  The  docking   results  display  a  disordered  NADPH  
binding  mode  for  N61D  (Fig.  5b),  similar  to  the  one  previously  observed  in  N78D  mutant  
of  bFMO  [31].  The  crystal  structures  of  bFMO  [7]  and  yFMO  [9]  show  that  the  NADP+  
amide  group  hydrogen  bonds  to  flavin  N5,  and  the  nicotinamide  sugar  moiety   is  also  
within  hydrogen-­bond  distance  from  the  conserved  Asn  residue.  If  the  latter  conserved  
residue   together   with   flavin   N5   helps   to   guide   and   position   NADPH   binding,   the  
disordered  NADPH  binding  modes  observed  in  the  two  mutants  would  rationalize  the  in  
vitro  experimental  data  obtained  i.e.  decrease  in  NADPH  binding  affinity.  Therefore,  both  
in  silico  and  in  vitro  data  suggest  that  mutations  of  conserved  amino  acid  61  will  result  
in  poor  NADPH  binding  affinity.     
  
3.4.   NADP+  and  Asn61  stabilize  FAD  intermediate     
It  is  known  that  after  flavin  reduction  by  NADPH,  the  resulting  NADP+  stays  bound  
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close  to  the  FAD  cofactor  [6,  32].  The  ITC  data  obtained  for  N61Q  are  shown  in  Fig.  6a  
with  saturation  at  a  molar  ratio  of  around  10  resulting  in  a  calculated  Kd  value  of  56.3  
μM.  This  value  is  an  order  of  magnitude  higher  than  the  value  previously  reported  for  
the  WT  hFMO3  (Kd  of  3.7  μM)  [19].  However,  the  data  suggest  that  N61Q  does  still  bind  
NADP+.     
On   the  other  hand,  experiments  carried  out  with  N61D  mutant,  demonstrate   that  
titration  with  even  higher  concentrations  of  NADP+,  up   to  20  mM,  do  not   result   in  an  
observed  binding  curve   (a  higher  concentration  will   result   in  a  significant   increase   in  
heat  of  dilution),  as  shown  in  Fig.  6b.  These  data  suggest  that  mutations  of  the  Asn  61  
cause   changes   in   the   binding   affinity   of   NADP+   and   in   the   specific   case   of   charge  
reversal,  N61D,  no  binding  is  observed.  The  corresponding  data  of  the  wild-­type  hFMO3  
has  been  recently  reported  by  our  group  [19].     
In  general,  as  mentioned  earlier,  it  is  accepted  that  NADP+  binds  and  remains  in  the  
active  site  of  FMO  stabilising  the  C4a-­hydroperoxyflavin  intermediate  [6,  32].  Since  the  
two  mutants  have  poor  NADP+  binding  affinity,  the  logical  subsequent  experiment  was  
to  investigate  the  stability  of  the  FAD  intermediates  of  N61D  and  N61Q.  To  this  end,  the  
formation   and   decay   of   C4a-­hydroperoxyflavin   intermediate   of   the   two  mutants  was  
monitored   by   stopped-­flow   spectroscopy.   Disproportionate   increase   in   absorbance  
peaks   at   381   nm   and   450   nm   (red   spectra   in   Fig.   7a   and   b),   are   indicative   of   the  
intermediate   formation  and  subsequent  decay.  As  a  consequence  of   the  overlapping  
absorbance   maxima   around   381   nm   of   both   FAD   and   C4a-­hydroperoxyflavin  
intermediate  (Fig.  7a),  the  intermediate  was  determined  by  the  following  equation  (2)  as  
previously  reported  [19].  A456 789:;<:=>?9: = A456 − AABC − (AEBC − AABC)×	  ,IJK(LMNN	  '(OPQ)RSQOT)U,VWX(LMNN	  '(OPQ)RSQOT),YWX(LMNN	  '(OPQ)RSQOT)U,VWX(LMNN	  '(OPQ)RSQOT)   (Eq.  2)  
  
No  intermediate  was  observed  for  N61D  mutant  under  the  experimental  conditions  
(Fig.  7b  and  d).  In  the  case  of  N61Q  mutant,  compared  to  WT-­hFMO3  [19],  intermediate  
formation   was   not   only   slower   but   once   formed,   decayed   faster   indicative   of   the  
instability  of  this  intermediate  (Table  5).     
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Table  5  Kinetic  parameters  of  C4a-­hydroperoxyflavin  intermediate  stability  in  wild  type  
and  mutant  hFMO3  
  
hFMO3  
   Intermediate  (381  nm)  
  
kformation     
(s-­1)  
Kdecay     
(s-­1)  
WT  [19]      1.5801   0.0014  
N61Q      0.8170   0.0038  
N61D      Not  detectable  
  
In   the  oxidative  half-­reaction,  FMO  requires   the  binding  of  NADP+   to  stabilize   the  
C4a-­(hydro)peroxyflavin  before  substrate  access.  Three  features  of  the  NADP+  are  well  
established:   its   nicotinamide   moiety   together   with   side   chain   of   the   conserved   Asn  
residue  and  flavin  C4a-­N5  atoms  define  an  O2  reacting  crevice  [31];;  proton  transfer  from  
the  2’-­OH  of  the  nicotinamide  ribose  to  the  C4a-­peroxyflavin  results  in  the  formation  of  
the   C4a-­hydroperoxyflavin;;   NADP+   is   stacked   and   hydrogen   bonds   with   the  
isoalloxazine  ring  to  protect  the  C4a-­(hydro)peroxyflavin  from  decay  [7,  31].     
The  docking  results  of  NADP+  shown  in  Fig.  8a  illustrate  that  NADP+,  located  above  
the  isoalloxazine  ring,  together  with  Asn  61  shield  flavin  N5  and  the  C4a-­hydroperoxide  
intermediate  from  solvent  in  the  WT-­hFMO3.  While  for  the  binding  mode  of  N61D  (Fig.  
8b),  the  nicotinamide  moiety  is  flipped  out  exposing  the  flavin  N5  atom  and  its  adjacent  
C4a-­adduct  intermediate  to  the  solvent,  which  will  lead  to  the  destabilisation  of  the  C4a-­
hydroperoxyflavin   intermediate.   In   addition,   the   intermediate   instability   can   be  
exacerbated  by  the  repulsive  interaction  between  the  negatively  charged  side  chain  of  
N61D  mutant  and  the  C4a-­hydroperoxide  (Fig.  8b).     
For  N61Q  mutant,  the  binding  mode  of  NADP+  is  also  altered  although  still  on  the  
side   of   flavin   C4a-­N5   with   the   bulkier   glutamine   side-­chain   stretching   above   the  
intermediate  and  shielding  it  in  the  same  way  as  the  WT  (Fig.  8c).     
These   in  silico  data  are  in  support  of  the  experimental  data  where  N61D  mutation  
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converts   the   enzyme   from  a  monooxygenase   to   an   oxidase  with   undetectable  C4a-­
hydroperoxyflavin   intermediate   (Fig.   7d),   whilst   the   N61Q   still   has   a   detectable  
intermediate  (Fig.  7c).  Taken  together,  these  data  indicate  NADP+  together  with  the  side-­
chain  of  Asn61  pose  a  protective  barrier  which  is  favourable  for  C4a-­hydroperoxyflavin  
intermediate  stability.  
  
4.   Discussion  
In  this  work,  the  binding  of  substrate/inhibitor  to  hFMO3  was  investigated  both  by  means  
of  in  vitro  as  well  as  in  silico  experiments.  Although  the  crystal  structures  of  the  yeast  
and  bacterial  FMOs  were  published  more  than  a  decade  ago  [7,  9],  no  structure  is  yet  
available  for  any  of  the  human  FMOs.  In  the  absence  of  such  structural  information,  site-­
directed  mutagenesis  (based  on  bacterial  and  yeast  known  structures)  can  confirm  to  
some  degree  the  correctness  of  available  in  silico  3D  models,  especially  the  catalytic  
pocket   of   the  protein.  Once   the   latter   has  been  proven,   as   is   the   case   in   this  work,  
docking   experiments   can   be   carried   out   to   compare   and   contrast   the   binding   of   a  
substrate   as   opposed   to   an   inhibitor   and   finally   guide   the   development   of   hFMO3  
inhibitors.  
Literature  data  show   that   to  date,  only  a  very   few   true  competitive   inhibitors  of  FMO  
have   been   identified,   and   most   of   these   compounds   which   lead   to   decrease   FMO  
enzymatic  activity  are  alternate  substrate  competitive  inhibitors  [33].  Cashman  and  his  
co-­workers  [33]  reported  indole-­3-­carbinol  (I3C)  and  its  acid-­treated  products,  I33’  and  
LT,  as  potent  inhibitors  of  hFMO3.  Methimazole  is  another  known  hFMO3  substrate  and  
competitive  inhibitor.  To  the  best  of  our  knowledge,  the  inhibitory  mechanism  of  these  
compounds  on  hFMO3  have  never  been  studied   from  a  structural  view  point.  The   in  
vitro   and   in   silico   data   presented   in   this   work,   demonstrates   that   the   Pi-­stacking  
interactions  of  these  aromatic  compounds  to  the  isoalloxazine  ring  of  the  FAD  cofactor  
is  responsible  for  and  contributes  to  the  observed  hFMO3  inhibition.     
Future   work   will   focus   on   the   screening   of   aromatic   chemicals   in   order   to   discover  
potential  hFMO3  inhibitors  with  strong  inhibitory  effects,  due  to  the  striking  association  
of  hFMO3  inhibition  with  atherosclerosis  treatment  and  prevention.  
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Figure  legends  
  
Fig.  1  UV-­Vis  spectra  (300-­550  nm)  of  WT-­hFMO3,  N61Q  and  N61D.  Protein  spectra  
(3.5  μM)  were  recorded  in  0.1  M  phosphate  buffer  (pH  7.4),  20%  glycerol,  1  mM  EDTA.  
  
Fig.  2  Docking  results  of  hFMO3  with  methimazole  (MMI).  (a)  WT  plus  MMI;;  (b)  N61Q  
plus  MMI;;  (c)  N61D  plus  MMI;;  Docking  performed  by  YASARA  structure  package  and  
results  analyzed  by  DS  Visualizer.  The  conventional  hydrogen  bond  is  in  green,  the  Pi-­
Pi   stacking   interaction   of   MMI   and   isoalloxazine   ring   in   magenta   with   the   stacking  
distance  indicated.  FAD  fluorescence  changes  upon  MMI  addition  for  (d)  WT-­hFMO3,  
(e)  N61Q  and  (f)  N61D.  
  
Fig.  3  Co-­crystal   structures  of   (a)   Indole-­bFMO   (PDB   ID:  2XVJ)  and   (b)  MMI-­yFMO  
(PDB  ID:  2GVC)  show  the  substrate  Pi-­stacking  with  isoalloxazine  ring  of  FAD  and  Pi-­
Pi   interactions  (T-­shaped)  with  an  aromatic  residue  nearby  (cyan).  Molecular  docking  
experiment   shows   similar   Pi-­stacking   binding   mode   in   (c)   MMI/hFMO3.   Pi-­Pi  
interactions   are   in   black   dotted   lines,   FAD   in   orange.   The   Pi-­Pi   interactions   were  
monitored  by  DS  Visualizer  and  figures  were  generated  with  PyMOL.  
  
Fig.  4  Inhibition  of  the  methimazole  (MMI)  S-­oxygenation  catalyzed  by  (a)  WT-­hFMO3,  
(b)  N61Q  and  (c)  N61D  by  indole  and  the  type  of  enzyme  inhibition  determined  by  (d)  
Lineweaver-­Burk  plot  (each  data  point  is  the  mean  from  at  least  three  experiments).  
  
  
Fig.   5   Docking   of   NADPH   to   hFMO3  model   (a)  WT,   (b)   N61D   and   (c)   N61Q.   The  
distance  from  residue  61  side-­chain  to  flavin  C4a-­N5  was  measured  by  DS  visualizer.  
NADPH  is  in  yellow,  FAD  in  magenta,  residue  61  in  green.  Oxygen  atoms  are  in  red  with  
nitrogen  in  blue.  Docking  performed  by  YASARA  structure  package.  
  
Fig.  6  Isothermal  titration  calorimetry  data  for  hFMO3  mutants  (a)  N61Q  and  (b)  N61D  
binding  with  NADP+.  The  experiments  were  performed  by  titration  of  NADP+  (20  mM  for  
N61D  and  2  mM  for  N61Q)  into  the  protein  solution  (20  μM).  
  
Fig.  7  The  re-­oxidation  spectra  of  reduced  hFMO3  mutants:  (a)  N61Q  and  (b)  N61D  at  
three  different  time  points.  Kinetics  of  formation  and  decay  of  the  C4a-­hydroperoxyFAD  
intermediates  followed  at  381  nm:  (c)  N61Q  and  (d)  N61D.  The  figure  insets  show  the  
same  absorbance  for  the  first  five  seconds.  
  
Fig.   8   Docking   results   of   the   C4a-­hydroperoxyflavin   intermediate   with   NADP+   for  
hFMO3  (a)  WT,  (b)  N61D  and  (c)  N61Q.  The  –OOH  group  at  flavin  C4a  position  was  
modelled   in   the   NADP+-­free   protein   followed   by   the   docking   with   NADP+.   The   best  
docking  result  with  highest  score  was  selected  for  analysis.  FAD  and  amino  acid  61  are  
displayed  in  dots  showing  the  van  der  waals  radii.  NADP+  is  in  yellow  with  FAD  in  cyan.  
Docking  performed  by  YASARA  structure  package.  
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Table  S1  DSC  data  for  wild-­type  hFMO3  at  different  scan  rates  (heating  rates)  with  the  calculated  Tm  and  












     
  
	  	   	  	   Peak	  1	   	  	   Peak	  2	  
Heating	  rate	   	  	   Tm	  (°C)	   ΔH	  Kcal/mol	   	   Tm	  (°C)	   ΔH	  Kcal/mol	  
180	  °C/h	   	   50.53	   59.9	   	   55.96	   25.8	  
90	  °C/h	   	   48.78	   50.3	   	   54.66	   29.2	  
30	  °C/h	   	   45.09	   11	   	   49.02	   38.4	  






Figure  S1  SDS-­PAGE  analysis  of  purified  WT-­hFMO3  and  its  two  mutants  N61D  and  N61Q.  
The  protein  band  around  60  kDa  is  in  good  agreement  with  the  theoretical  molecular  weight  
calculated  from  the  amino  acid  sequence.  
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Figure   S2   DSC   data   for   (a)   N61D   and   (c)   N61Q   mutants   of   hFMO3   together   with   the  
deconvoluted  DSC  profiles:  (b)  N61D;;  (d)  N61Q.  Protein  concentration  was  10  μM  in  50  mM  
phosphate  buffer,  pH  7.4.     
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Figure  S3  Michaelis-­Menten  curves  of  wild  type  and  the  two  mutants  of  hFMO3.  
  
  
     










Figure  S4  (a)The  superimposed  HPLC  chromatograms  of  the  reaction  of  hFMO3  with  indole  
after   30  minutes’   incubation   at   37   °C.   (b)   NADPH   consumption   assay   by   hFMO3   in   the  
presence  of  different  concentrations  of  indole.  
  
